ERBB2 and breast cancer: Specifically, for HER2-positive BC, the GeparQuattro trial defined that the detection of ≥2 CTCs/7.5 mL was associated with a reduced DFS in a multivariate analysis, suggesting that some of these preoperatively detected CTCs are resistant to therapies and lead to subsequent relapse (Table 1).